Etanercept

CHEMBL1201572 Phase 4 Aprovado Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

This biologic medication blocks TNF-alpha, a protein that causes the harmful inflammation found in conditions like rheumatoid arthritis, psoriasis, and ankylosing spondylitis. Regular injections help reduce joint damage, skin symptoms, and overall disease activity.

Áreas Terapêuticas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

This biologic medication blocks TNF-alpha, a protein that causes the harmful inflammation found in conditions like rheumatoid arthritis, psoriasis, and ankylosing spondylitis. Regular injections help reduce joint damage, skin symptoms, and overall disease activity.

Yes, Etanercept is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201572. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.